Alnylam Pharmaceuticals, Inc. vs ProShares Ultra Semiconductors — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $224.01 (market cap $29.60B), while ProShares Ultra Semiconductors trades at $94.53. The key difference: ProShares Ultra Semiconductors is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | USD | |
|---|---|---|
Market Cap | $29.60B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $491.22 | $113.53 |
52-Week Low | $205.48 | $40.97 |
Enterprise Value | $27.56B | — |
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $216.98, down 1.01% with bearish technical signals. The company shows strong revenue growth from $1.0B in 2022 to $3.7B in 2025, turning profitable with $314M net income. However, recent Q2 2026 earnings missed expectations, and multiple law firms are investigating potential securities fraud. Analyst consensus remains bullish with a $370.07 price target despite recent volatility.
The stock faces near-term pressure from legal investigations and earnings volatility, but strong fundamentals and analyst support suggest long-term potential. Key risks include legal outcomes and execution on growth targets, while the 71% upside to consensus target offers opportunity if the company can maintain its revenue trajectory.
USD stock trades at $94.98, up 6.62% over 24 hours, with a bullish technical signal from moving averages and a neutral stance from oscillators. The stock shows strong momentum but trades near key resistance at $93. Recent news highlights corporate developments including a dividend announcement scheduled for June 2026, though fundamental data such as P/E and revenue metrics are currently unavailable.
The outlook for USD is cautiously optimistic given technical strength, but limited fundamental data and high RSI levels suggest potential near-term volatility. Investors should weigh the bullish trend against the absence of key financial metrics and elevated technical indicators before making decisions.
Trailing returns across standard periods
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →USD is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Dow Jones U.S. Semiconductors™ Index. It is a tactical instrument designed for sophisticated traders looking to magnify short-term bullish views on the U.S. semiconductor industry, specifically focusing on large-cap leaders in the chip and equipment space.
Read more on USD →